Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study - Scorecard - MDSpire
Advertisement
Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study
Clinical Scorecard: Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study
At a Glance
Category
Detail
Condition
Moderate to Severe Plaque Psoriasis
Key Mechanisms
Secukinumab targets IL-17A, providing rapid and sustained efficacy.
Target Population
Adult patients with active moderate to severe plaque psoriasis.
Care Setting
Real-world clinical practice across Europe and Israel.
Key Highlights
High treatment retention rates over 5 years.
Sustained effectiveness in skin clearance and quality of life.
Consistent safety profile with low incidence of serious adverse events.
Importance of early intervention for better long-term outcomes.
Real-world evidence supports secukinumab as a valuable long-term treatment option.
Guideline-Based Recommendations
Diagnosis
Diagnosis of active moderate to severe plaque psoriasis by treating physician.
Management
Secukinumab should be administered according to the approved product label.
Monitoring & Follow-up
Regular assessments every 6 months for treatment retention and effectiveness.
Risks
Monitor for treatment-emergent adverse events and serious adverse events.
Patient & Prescribing Data
Approximately 2700 patients enrolled, with diverse backgrounds across Europe and Israel.
Patients received secukinumab for at least 16 weeks prior to study enrollment.
Clinical Best Practices
Encourage early initiation of secukinumab for optimal long-term management.
Utilize PASI and DLQI scores for effectiveness assessment.
Document patient-reported outcomes to gauge quality of life improvements.
by Matthias Augustin, Paul-Gunther Sator, Ralph von Kiedrowski, Dimitris Rigopoulos, Marco Romanelli, Pierre-Dominique Ghislain, Tiago Torres, Dimitrios Ioannides, Cynthia Vizcaya, Andreas Clemens, Weibin Bao, Christelle C. Pieterse, Barbara Schulz, Piotr Jagiello, Curdin Conrad
